Duloxetine Bottles Recalled Over Cancer-Linked Impurity

The FDA announced a Class II recall on June 15, 2026, for specific lots of duloxetine capsules, a generic for Cymbalta, distributed by Breckenridge Pharmaceutical from Spain-made stock. The issue is N-nitroso-duloxetine exceeding safe limits, though no adverse events are reported and the cancer risk remains theoretical for short-term use. This follows earlier 2026 and prior-year recalls, prompting online shares of withdrawal struggles like brain zaps alongside defenses that nitrosamines appear in everyday foods too. The FDA urges checking lot numbers, like 241180C expiring April 2027, and consulting doctors before changes to avoid worsening symptoms. This story is a summary of posts on X and may evolve over time. Grok can make mistakes,